Nureca Limited vs Sun Pharmaceutical Industries Limited

A side-by-side comparison of Nureca Limited (NURECA) and Sun Pharmaceutical Industries Limited (SUNPHARMA) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, Sun Pharmaceutical Industries Limited leads NURECA vs SUNPHARMA on 10 of 14 metrics (1 undecided). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation22
  • Profitability04
  • Growth01
  • Size & financial health13
ValueReturnsMarginGrowthScaleLow debt

Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.

Valuation

Even

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

149.08
P/E ratio
36.79
1.80
P/B ratio
5.35
0.87%
Dividend yield
0.86%
₹2.18
EPS
₹47.80

Profitability

SUNPHARMA takes 4/4

How efficiently each company turns capital and sales into profit. Higher is better.

0.00%
Return on equity
13.74%
3.42%
Return on capital
17.46%
0.12%
EBITDA margin
30.33%
1.42%
Net margin
19.69%

Growth

SUNPHARMA takes 1/2

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

9.81%
Revenue CAGR (3Y)
10.03%
—
Profit CAGR (3Y) even
10.57%

Size & financial health

SUNPHARMA takes 3/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹313 Cr
Market cap
₹4.22L Cr
₹147 Cr
Revenue
₹58,462 Cr
₹2 Cr
Net profit
₹11,509 Cr
0.01
Debt / equity
0.06
Nureca Limited
  • + ["Company is almost debt free."]
  • − ["The company has delivered a poor sales growth of -7.2% over past five years.", "The company has delivered a poor profit growth of -46.2% over past five years.", "Company has a low return on equity of 0.2% over last 3 years."]
Sun Pharmaceutical Industries Limited
  • + ["Company has delivered good profit growth of 38.3% CAGR over last 5 years", "Company has been maintaining a healthy dividend payout of 33.4%", "Company is almost debt free."]
  • − ["Stock is trading at 5.05 times its book value"]
Nureca Limited full analysis Sun Pharmaceutical Industries Limited full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.